RxDoctor Payments Data

Richard Chitsey, MD

Internal Medicine · Harrison, ARNPI 1679547301

Payments from drug & device makers

$101in general payments, 2019–2025

Across 7 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$24
  • Novo Nordisk$20
  • Amgen$16
  • Pfizer$15
  • AbbVie$14
  • AstraZeneca$13

What the payments were for

  • Food & beverage$101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.2$24
Novo Nordisk1$20
Amgen1$16
Pfizer1$15
AbbVie1$14
AstraZeneca1$13

How this compares

$101 in reported general payments places this provider in the 35th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$530,857
Medicare patients
2,275
Services billed
9,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban614$271,637
IngrezzaValbenazine Tosylate17$118,378
XareltoRivaroxaban203$101,609
JanuviaSitagliptin Phosphate138$101,185
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$84,672
OzempicSemaglutide80$82,062
MyrbetriqMirabegron125$55,964
Invega SustennaPaliperidone Palmitate13$51,055
LinzessLinaclotide76$48,392
FarxigaDapagliflozin Propanediol65$40,313
Breo ElliptaFluticasone/Vilanterol61$39,717
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog55$39,162
JardianceEmpagliflozin75$37,186
ZenpepLipase/Protease/Amylase23$36,826
Risperdal ConstaRisperidone Microspheres52$32,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$271,637614 claims
Novo NordiskOzempic$20$82,06280 claims
AstraZenecaFarxiga, Symbicort, Brilinta$13$81,283191 claims
AbbVieLinzess, Creon$14$64,40990 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Harrison

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →